Press Release

Date: 26th October, 2026 To, To, BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400 051 Ref.: BSE Scrip Code No. “533138” Ref.: “ASTEC” Debt Segment NSE: NCD-ASTEC-ISIN: INE563J08023 Dear Sir / Madam, Sub.: Press Release The Board of Directors of Astec LifeSciences Limited (“the Company”), at its Meeting held on Monday, 26th October, 2026, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Half Year ended 30th September, 2026. We enclose a copy of the Press Release and the same is being placed on the website of the Company (www.godrejastec.com). Please take the above information on your records. Thanking you, Yours sincerely, For Astec LifeSciences Limited Tejashree Pradhan Company Secretary & Compliance Officer (FCS 7167) Encl.: As above ASTEC LIFESCIENCES LIMITED “Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India CIN: L99999MH1994PLC076236 PRESS RELEASE Mumbai, 26th October 2026: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the second quarter and first half of FY27. FINANCIAL OVERVIEW Particulars (₹ cr) Q2FY27 Q2FY26 % Change H1FY27 H1FY26 % Change Total Income 72.6 74.8 (3%) 156.9 166.4 (6%) Earnings before Depreciation, (19.2) (5.6) n.m. (19.1) (16.1) n.m. Interest and Tax (EBITDA) Profit/(Loss) before Tax (37.4) (24.4) n.m. (56.2) (57.4) n.m. Profit/(Loss) after Tax (37.4) (24.4) n.m. (56.1) (57.4) n.m. n.m.: not measurable Q2 FY27 Financial Summary • Consolidated total income of ₹72.6 crore in Q2 FY27 vs. ₹74.8 crore in Q2 FY26. • Consolidated EBITDA of (₹19.2 crore) in Q2 FY27 vs. (₹5.6 crore) in Q2 FY26. • Reported loss after tax of (₹37.4 crore) in Q2 FY27 vs. (₹24.4 crore) in Q2 FY26. H1 FY27 Financial Summary • Consolidated total income of ₹156.9 crore in H1 FY27 vs. ₹166.4 crore in H1 FY26. • Consolidated EBITDA of (₹19.1 crore) in H1 FY27 vs. (₹16.1 crore) in H1 FY26. • Reported loss after tax of (₹56.1 crore) in Q2 FY27 vs. (₹57.4 crore) in H1 FY26. CHAIRPERSON’S COMMENTS Commenting on the performance, Mr. Vishal Sharma, Chairperson, Astec LifeSciences Limited, said: The demand across key agrochemical markets worsened due to adverse weather conditions in certain regions, elevated channel inventories, and cautious procurement by customers. We are seeing the El Niño impact and that combined with poor rainfall in many parts of India has led to a demand weakening. Export sales were further impacted by channel destocking, overall pricing pressure, and weaker demand across select export markets as the overall sentiment is one of caution. Astec reported consolidated income of ₹72.6 crore in Q2 FY27 versus ₹74.8 crore in Q2 FY26. The Company’s EBITDA was (₹19.2 crore) in the quarter as compared to an EBITDA of (₹5.6 crore) in the same period last year. Performance was impacted by lower volumes in its key enterprise products, reduced realizations and elevated input costs due to pricing pressures. In addition, ongoing geopolitical uncertainties have resulted in continued volatility in raw material prices, necessitating an inventory write down of Rs. 3 crore to net realizable value. Revenue from Enterprise Products stood at ₹57 crore in Q2 FY27, as compared to ₹61 crore in Q2 FY26, primarily led by lower volumes in its key enterprise molecules and reduced realizations. Revenue from CDMO Products grew by 15% y-o-y to ₹15 crore in Q2 FY27 compared to ₹13 crore in Q2 FY26. The Company is focused on expanding its growth platform through enhanced business development efforts and new product introductions, alongside ongoing initiatives to improve capacity utilizations, optimize costs, and strengthen operational performance. Revenue from Operations Q2FY27 Q2FY26 % Change H1FY27 H1FY26 % Change (₹ cr) Category Breakdown 72.0 73.7 (2%) 155.6 164.8 (6%) Enterprise 57.0 60.6 (6%) 108.7 97.1 12% Contract Manufacturing 15.0 13.1 15% 46.9 67.7 (31%) & New Products Geography Breakdown 72.0 73.7 (2%) 155.6 164.8 (6%) Exports 28.9 41.1 (30%) 62.2 87.0 (28%) Domestic 43.1 32.6 32% 93.4 77.8 20% About Astec LifeSciences Limited Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to several including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa. For more information on the Company, please log on to www.godrejastec.com For further information, please contact: Anurag Gupta Head, Investor Relations Godrej Agrovet Limited Email: anurag.gupta3@godrejagrovet.com Disclaimer: “Some of the statements in this communication may be ‘forward looking statements’ within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company’s operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations.”